Corporate News Blog - Ritter Pharma Announces Phase-3 Plans After End of Phase-2 Meeting with the FDA on RP-G28 for Lactose Intolerance
Research Desk Line-up: Ascendis Pharma Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 22, 2017 /Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=RTTR. The Company announced on August 18, 2017, its Phase-3 plans following the end of Phase-2 meeting with the US Food and Drug Administration (FDA) concerning the path forward for RP-G28 for the treatment of lactose intolerance (LI). The Company has incorporated guidance from the FDA on key elements of its Phase-3 program and received clear guidance and expectations on necessary components, including clinical, nonclinical, and chemistry, manufacturing and controls requirements necessary to support a successful new drug application (NDA) submission. For immediate access to our complimentary reports, including today's coverage, register for free now at:
Discover more of our free reports coverage from other companies within the Biotechnology industry. Pro-TD has currently selected Ascendis Pharma A/S (NASDAQ: ASND) for due-diligence and potential coverage as the Company announced on August 18, 2017, its financial results for Q2 2017 which ended on June 30, 2017. Tune in to our site to register for a free membership, and be among the early birds that get our report on Ascendis Pharma when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on RTTR; also brushing on ASND. Go directly to your stock of interest and access today's free coverage at:
The Meeting Highlights
Under terms of the announcement, Ritter Pharma announced that the Phase-3 clinical program will consist of two confirmatory clinical trials of similar trial design and size as the Company's Phase-2b/3 trial and will include additional components to allow for claims for durability of effect. The trials, according to the Company may run in parallel, where it anticipates initiating the Phase-3 program during the first half of 2018.
The protocol design, according to the announcement, will consist of multicenter, randomized, double-blind, placebo-controlled, parallel-group trials designed to determine the efficacy, safety, and durability of RP-G28 compared against placebo in subjects with lactose intolerance. The protocol design also includes screening to determine lactose intolerance, 30-day course of treatment, and 6-months of post-treatment observation. The primary endpoint will be the evaluation of a patient's composite LI symptoms, after a lactose challenge, comparing baseline symptom scores to 30-days post-treatment symptom to assess patient's clinically meaningful benefit. The secondary endpoint will evaluate LI signs and symptom and global assessment outcomes to evaluate and assess a patient's continued meaningful treatment benefit.
The Phase-2b/3 Trial and the RP-G28
The Phase-2b/3, multicenter, double-blind, placebo-controlled, parallel-group trial in 377 subjects was designed to determine the efficacy, safety, and tolerability of two dosing regimens of RP-G28 in subjects with lactose intolerance. RP-G28 is in fact, a novel, non-digestible oligosaccharide of ultra-high purity developed to module the gut microbiome by stimulating and adapting the bacteria in the gastrointestinal tract to metabolize lactose to improve lactose tolerance.
Under the trial, patients were assessed with lactose intolerance symptoms, measured on a Likert scale after a lactose challenge. Symptoms of abdominal pain, cramping, bloating, and movement were then combined into a composite endpoint representing the key symptoms of lactose intolerance. The composite primary endpoint was agreed to by the FDA prior to the unblinding the study results. The Phase-2b/3 trial design included a screening phase, a 30-day course treatment phase and post-treatment observation phase, during which subjects were followed while lactose-containing foods were reintroduced in their diets.
On August 03, 2017, Ritter Pharma announced additional findings and data analysis from its Phase-2b/3 study designed to evaluate lead candidate RP-G28 in subjects with lactose intolerance. These additional results from the trial analysis demonstrated that a clear drug effect was seen with a significant positive reduction in key symptoms of lactose intolerance and across a variety of global and real-world outcomes. The study demonstrated safety with no serious adverse events related to treatment.
Last Close Stock Review
On Monday, August 21, 2017, the stock closed the trading session at $0.57, dropping 4.50% from its previous closing price of $0.60. A total volume of 168.37 thousand shares have exchanged hands. Ritter Pharma's stock price rallied 0.53% in the last one month. The stock currently has a market cap of $7.45 million.
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
© 2017 Accesswire. All Rights Reserved.